LEXINGTON, Mass.--(BUSINESS WIRE)-- AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) today announced that management will host a conference call to provide an update on the company’s discussions with the U.S. Food and Drug Administration regarding an update to the product label for Feraheme® (ferumoxytol) Injection for intravenous (IV) use.
Conference Call and Webcast Access
AMAG Pharmaceuticals, Inc. will host an audio webcast and conference call on November 29, 2010 at 8:00 a.m. ET. To access the conference call via telephone, please dial (877) 412-6083 from the United States or (702) 495-1202 for international access. A telephone replay will be available from approximately 11:00 a.m. ET on November 29, 2010 through midnight December 1, 2010. To access a replay of the conference call, dial (800) 642-1687 from the United States or (706) 645-9291 for international access. The passcode for the live call and the replay is 27619200.
The call will be webcast and accessible through the Investors section of the Company’s website at www.amagpharma.com. The webcast replay will be available from approximately 11:00 a.m. ET on November 29, 2010 through midnight December 29, 2010.
About AMAG Pharmaceuticals, Inc.
AMAG Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of a therapeutic iron compound to treat iron deficiency anemia. AMAG manufactures and sells Feraheme® (ferumoxytol) Injection for intravenous (IV) use. For additional company or product information, please visit www.amagpharma.com or http://feraheme.com.
Feraheme is a registered trademark of AMAG Pharmaceuticals, Inc.
AMAG Pharmaceuticals, Inc.
Carol Miceli, 617-498-3361
KEYWORDS: United States North America Massachusetts
INDUSTRY KEYWORDS: Health Biotechnology Pharmaceutical